Monitor future Form 4 filings for actual transactions; the power of attorney simplifies compliance but does not indicate imminent buying or selling. Vesting schedule suggests incremental share releases starting late 2026.
ZYME drugs
ZYME drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $26.17entry
- T+1 · 7mo ago +3.10%α +1.89% · $26.98
- T+5 · 7mo ago +6.42%α +3.12% · $27.85
- T+20 · 6mo ago −8.18%α −15.91% · $24.03
- T+60 · 4mo ago +1.83%α −7.09% · $26.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Scott Platshon, EVP and Chief Business Officer of Zymeworks, filed a Form 3 disclosing initial beneficial ownership and granting a power of attorney to Catherine Graham and Wilson Sonsini to file required Section 16 reports on his behalf. The filing reveals no current holdings but includes previously granted stock options and RSUs.
Key Facts
- Scott Platshon is EVP, Chief Business Officer of Zymeworks
- Filed Form 3 to report initial beneficial ownership
- Granted power of attorney to Catherine Graham and Wilson Sonsini attorneys to file Section 16 forms
- Currently holds no beneficially owned securities
- Has stock options for 167,000 shares at $22.99, granted Nov 18, 2025, vesting 25% annually
- Has 111,111 RSUs granted Nov 18, 2025, vesting in three equal annual installments starting Nov 18, 2026
Financial Impact
No immediate financial impact; potential future dilution of approximately 0.28% of market cap ($5.6M) upon full vesting of options and RSUs
Risk Factors
- Future insider selling could create downward pressure
- Lack of current ownership may signal misalignment with shareholders
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 3 Filing (Primary) | 0001193125-26-151232 |
| Document: 0001193125-26-151232-index-headers.html | 0001193125-26-151232 |
| Document: 0001193125-26-151232-index.html | 0001193125-26-151232 |
| Document: 0001193125-26-151232.txt | 0001193125-26-151232 |
Track record
25 reports on ZYME
6 of 9 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 9 of 11 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
- Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
- Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers